Spinal Muscular Atrophy Type 2Symptoms, Doctors, Treatments, Advances & More
Spinal Muscular Atrophy Type 2 Overview
Learn About Spinal Muscular Atrophy Type 2
- Spinal muscular atrophy type 2
- Dubowitz disease
- Muscular atrophy, spinal, infantile chronic form
- Muscular atrophy, spinal, intermediate type
- SMA II
- SMA2
- Spinal muscular atrophy type II
UCLA Health Westwood Neurology
Perry Shieh is a Neurologist practicing medicine in Los Angeles, California. Dr. Shieh is rated as an Elite provider by MediFind in the treatment of Spinal Muscular Atrophy Type 2. He is also highly rated in 47 other conditions, according to our data. His clinical expertise encompasses Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Tubular Aggregate Myopathy.
Department Of Neurology
Basil Darras is a Pediatric Neurologist practicing medicine in Boston, Massachusetts. Dr. Darras is rated as an Elite provider by MediFind in the treatment of Spinal Muscular Atrophy Type 2. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 1, and Gastrostomy. Dr. Darras is currently accepting new patients.
Francesco Muntoni practices practicing medicine in London, United Kingdom. Mr. Muntoni is rated as an Elite expert by MediFind in the treatment of Spinal Muscular Atrophy Type 2. He is also highly rated in 46 other conditions, according to our data. His clinical expertise encompasses Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), and Gastrostomy.
Summary: This is a phase I/II clinical study to evaluate the safety, preliminary efficacy and immunogenicity of SKG0201 injection in subjects with Spinal Muscular Atrophy Type I.
Summary: GB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety, tolerability and efficacy of GB221 in two groups: 1. participants aged from 2 weeks to younger than 12 months presenting with symptoms of SMA Type 1 who have never received a treatment OR are receiving the drug risdiplam 2. partici...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center